News from pieris ag A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Apr 04, 2012, 05:00 ET Pieris Presents Preclinical Data for PRS-110 c-Met Antagonist Anticalin® at the AACR Annual Meeting

Pieris AG announced today the presentation of a range of in vitro and in vivo preclinical data for the company's proprietary c-Met antagonist...


Feb 07, 2012, 05:00 ET Pieris Receives BMBF Grant to Fund PRS-110c-Met Antagonist Anticalin(R) Program

Pieris AG announced today the receipt of a EUR 1 million grant to support the development of the company's proprietary PRS-110 compound targeting...


Dec 13, 2011, 05:19 ET Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin(R) Program at ASH Annual Meeting

-- Breadth of Pharmacokinetic Data Points to Tunable Half-life for Platform -- Pieris AG presented novel preclinical in vitro and in vivo data for...


Nov 15, 2011, 05:00 ET Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference

Pieris AG presented the results of the Company's first clinical evaluation of its most advanced Anticalin®, PRS-050, an anti-VEGF targeted protein...


Oct 19, 2011, 06:22 ET Pieris Outlines Strategic Impact of Six Million Euro EUROCALIN Grant Award on Anticalin® Pipeline Development

In concert with the award of the EU FP7 Grant to the Pieris-led EUROCALIN Consortium that will enable initial clinical development of Pieris'...


Oct 19, 2011, 05:50 ET EUROCALIN Consortium Initiates EU Grant Funded Collaboration to Develop Novel Anticalin Therapeutic to Treat Anemia

The EUROCALIN Consortium, comprising 10 companies and universities from across Europe, has initiated a collaboration focused on attaining and...


May 23, 2011, 05:00 ET Pieris Announces Preclinical In Vitro and In Vivo Data for its Anticalin(r) PRS-080 Hepcidin Antagonist Drug Program

Pieris AG announced today preclinical in vitro and in vivo data for its PRS-080 Anticalin antagonist program targeting hepcidin, a small peptide...


Apr 12, 2011, 05:00 ET Pieris and Daiichi Sankyo Sign Therapeutic Collaboration to Develop Anticalin(R) Therapeutics

Pieris AG announced today the signature of a collaboration and license agreement with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo;...


Apr 11, 2011, 05:00 ET Pieris to Present at BioCentury Future Leaders in the Biotech Industry Conference

Pieris AG announced today that Stephen Yoder, Chief Executive Officer, is scheduled to present at the 18th Annual BioCentury Future Leaders in the...


Feb 22, 2011, 03:59 ET Pieris to Present Interim Data From the Phase I Clinical Trial of PRS-050 at Molecular Medicine Tri-Conference

Pieris AG announced today the upcoming presentation of new preclinical and interim Phase I clinical trial data for its PRS-050 Anticalin(r) program,...


Jan 10, 2011, 05:00 ET Takeda San Francisco and Pieris Sign Anticalin(R) Therapeutic Collaboration

Takeda San Francisco (TSF) and Pieris AG have signed a drug discovery partnership agreement under which Pieris will apply its Anticalin(R) scaffold...


Sep 28, 2010, 07:37 ET Pieris Signs Broad Collaboration With Sanofi-Aventis and Sanofi Pasteur to Develop Anticalin Therapeutics

Pieris AG (http://www.pieris-ag.com/) announced today the signature of a collaboration and license agreement with both Sanofi-Aventis and Sanofi...


Jun 15, 2010, 06:01 ET Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound

Pieris AG announced today the initiation of a Phase I clinical trial in cancer patients for its lead program, PRS-050, an anti-VEGF Anticalin. The...


Jun 07, 2010, 04:57 ET Pieris AG Appoints Chief Scientific Officer

Pieris AG announced today that Laurent Audoly, Ph.D., has joined the company as Chief Scientific Officer, effective immediately. Dr. Audoly, most...


Apr 30, 2010, 08:59 ET Pieris Announces Positive Preclinical Data on c-Met Anticalin Drug Program

Pieris AG announced today preclinical data for its proprietary PRS-110 Anticalin(R) compound, which targets the c-Met receptor, demonstrating a...


Jan 04, 2010, 04:10 ET Pieris Appoints a New CEO

Pieris AG today announced the appointment of Stephen S. Yoder as CEO with immediate effect. Mr. Yoder takes over the position from interim CEO and...